Related Experiment Videos
[Bone marrow graft in hereditary diseases].
W Bujan1, A Ferster, C Devalck
1Unité d'Hémato-Oncologie, Hôpital Universitaire des Enfants, Bruxelles.
Revue Medicale De Bruxelles
|June 1, 1992
Summary
Bone marrow transplantation (BMT) has been a primary treatment for hereditary disorders since 1968. Advances in supportive care and immunology have improved outcomes, making BMT a crucial curative option.
Area of Science:
- Hematology
- Immunology
- Genetics
Context:
- Bone marrow transplantation (BMT) has been a cornerstone therapy for hereditary metabolic and immunological disorders since 1968.
- Significant advancements in supportive care and a deeper understanding of BMT complication immunology have enhanced treatment efficacy.
- These improvements have led to better disease correction and increased long-term survival rates for patients.
Purpose:
- To review the historical and current role of bone marrow transplantation in treating hereditary disorders.
- To highlight the impact of supportive care and immunological advancements on BMT outcomes.
- To discuss emerging therapeutic strategies and the continued importance of BMT.
Summary:
- BMT has evolved from an experimental procedure to a first-line therapy for specific hereditary conditions.
- Improved supportive care and immunological insights have boosted disease correction and survival.
- While new treatments like gene therapy are emerging, BMT remains the sole curative option for select disorders.
Impact:
- Enhanced survival and quality of life for individuals with previously untreatable hereditary diseases.
- Established BMT as a critical therapeutic modality in managing complex genetic and immune deficiencies.
- Paved the way for future research into regenerative medicine and personalized genetic therapies.